Using NESP to Treat Anemia in Cancer Patients
Author Information
Author(s): Smith R E Jr, Jaiyesimi I A, Meza L A, Tchekmedyian N S, Chan D, Griffith H, Brosman S, Bukowski R, Murdoch M, Rarick M, Saven A, Colowick A B, Fleishman A, Gayko U, Glaspy J
Primary Institution: South Carolina Oncology Associates
Hypothesis
Can novel erythropoiesis stimulating protein (NESP) safely increase hemoglobin levels in anemic patients with non-myeloid malignancies not receiving chemotherapy?
Conclusion
NESP was well tolerated and effectively increased hemoglobin levels in anemic cancer patients.
Supporting Evidence
- NESP has a longer serum half-life compared to erythropoietin.
- NESP can maintain hemoglobin levels effectively with less frequent dosing.
- Patients responded positively to increasing doses of NESP.
Takeaway
This study tested a new treatment for anemia in cancer patients, and it worked well without causing serious side effects.
Methodology
NESP was administered at varying doses for a maximum of 12 weeks under physician supervision.
Participant Demographics
Patients with non-myeloid malignancies not receiving chemotherapy.
Statistical Information
Confidence Interval
95% confidence interval ranged from 42% to 94% for patient response rates.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website